Searched for: in-biosketch:true
person:givib01
Utilization of Immunotherapy in Head and Neck Cancers Pre-Food and Drug Administration Approval of Immune Checkpoint Inhibitors [Meeting Abstract]
Wu, S. P. P.; Tam, M.; Gerber, N. K.; Li, Z.; Schmidt, B.; Persky, M.; Sanfilippo, N. J.; Tran, T.; Jacobson, A.; DeLacure, M.; Hu, K. S.; Persky, M.; Schreiber, D. P.; Givi, B.
ISI:000428145600179
ISSN: 0360-3016
CID: 3035562
Utilization and Survival of Postoperative Radiation or Chemoradiation for pT1-2N1M0 Head and Neck Cancer
Lee, Anna; Givi, Babak; Roden, Dylan F; Tam, Moses M; Wu, S Peter; Gerber, Naamit K; Hu, Kenneth S; Schreiber, David
Objective To analyze the patterns of care and survival for pT1-2N1M0 head and neck cancer based on receipt of surgery alone, surgery + postoperative radiotherapy (S + RT), or surgery + postoperative chemoradiotherapy (S + CRT). Study Design Retrospective analysis. Setting National Cancer Database. Subjects and Methods We queried the database for patients with stage pT1-2N1M0 squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx, or larynx between 2004 and 2012 who were treated with surgery with negative margins and no extracapsular extension. Logistic regression was used to assess predictors of receipt of postoperative treatment. Overall survival was assessed by the Kaplan-Meier method, and Cox regression analysis identified covariates that affected it. Results There were 1598 patients included in this study: 566 (35.4%) received surgery alone; 726 (45.4%), S + RT; and 306 (19.1%), S + CRT. The 5-year overall survival was 68.8%, 74.0%, and 87.8%, respectively ( P = .009 comparing S + RT and surgery alone, P < .001 for all other comparisons). On multivariable logistic regression, academic centers were associated with a decreased likelihood of S + RT (odds ratio = 0.71) and S + CRT (odds ratio = 0.66). Multivariable Cox regression demonstrated no difference in survival for S + RT over surgery alone (hazard ratio = 0.88, 95% CI = 0.70-1.09, P = .24); however, there was a survival benefit associated with S + CRT (hazard ratio = 0.57, 95% CI = 0.39-0.81, P = .002). Conclusion Nearly 65% of patients with pT1-2N1 head and neck cancer with negative margins and no extracapsular extension received S + RT or S + CRT. Improvement in survival was noted only for patients who received S + CRT.
PMID: 29256329
ISSN: 1097-6817
CID: 3063362
AHNS Series: Do you know your guidelines? Evidence-based management of oral cavity cancers
Gill, Amarbir; Vasan, Nilesh; Givi, Babak; Joshi, Arjun
Oral cavity squamous cell carcinoma (OCSCC) is the most common nonmelanoma head and neck cancer in the world, with an estimated 405Â 000 new cases expected each year. Subsites of the oral cavity include the alveolar ridge, buccal mucosa, anterior tongue, tonsillar pillar, retromolar trigone, hard palate, gingiva, and floor of the mouth. In this issue of the AHNS "Do you know your guidelines?" series, we review the evidence-based approach to the management of oral cavity carcinomas based on the framework provided by the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology.
PMID: 29206324
ISSN: 1097-0347
CID: 2915662
Impact of Adjuvant Radiotherapy for Malignant Salivary Gland Tumors
Safdieh, Joseph; Givi, Babak; Osborn, Virginia; Lederman, Ariel; Schwartz, David; Schreiber, David
Objective Using the National Cancer Database (NCDB), we investigated the characteristics, outcomes, and benefits of adjuvant therapy for patients diagnosed with malignant salivary gland tumors between 2004 and 2012. Study Design Retrospective analysis. Setting NCDB. Subject and Methods The cases of patients diagnosed with a nonmetastatic major salivary gland tumor who underwent resection between 2004 and 2012 were abstracted from the NCDB. Patients were further included if they had pT1-4NX-1M0 high-grade disease or pT3-4NX-0M0 or pT1-4N1M0 low-grade disease. Patients were identified as having no postoperative radiation therapy or having received postoperative radiation therapy to a dose of 5000 and 7000 cGy to the head and neck region or the parotid region, and their characteristics and outcomes were compared. Results During the study period, 4068 patients met the inclusion criteria for this analysis, of which 2728 (67.1%) received postoperative radiation and 1340 (32.9%) did not. With a median follow-up of 49.1 months, there was a significant improvement in overall survival associated with those receiving postoperative radiation (5 years, 56% vs 50.6%). On multivariable analysis, radiation utilization (hazard ratio, 0.78; 95% CI, 0.71-0.86; P < 0.001) and female sex (hazard ratio, 0.88) were associated with improved survival. When the analysis was limited to patients =65 years old, the survival benefit was persistent on multivariable analysis. Conclusion In conclusion, in this large NCDB study of 4068 patients with locally advanced malignant salivary gland carcinoma, administering adjuvant radiotherapy was associated with improved overall survival.
PMID: 28675085
ISSN: 1097-6817
CID: 2617242
Patterns of care and impact of brachytherapy boost utilization for squamous cell carcinoma of the base of tongue in a large, national cohort
Lee, Anna; Givi, Babak; Wu, S Peter; Tam, Moses M; Gerber, Naamit K; Hu, Kenneth S; Han, Peter; Schreiber, David
PURPOSE: The National Cancer Data Base was analyzed to evaluate the patterns of care and impact of brachytherapy (BT) boost on overall survival (OS) for patients with squamous cell carcinoma of the base of tongue. METHODS AND MATERIALS: Patients with nonmetastatic squamous cell carcinoma of the base of tongue between 2004 and 2012 who received concurrent external beam radiation therapy (EBRT) and chemotherapy with or without BT boost in the definitive setting were queried. Overall survival was assessed by the Kaplan-Meier method. Cox regression analysis was used to identify covariates that affected OS. RESULTS: There were 15,934 patients included in this study; 137 (0.9%) received EBRT + BT and the remaining received EBRT only. Median followup was 41.2 months. The utilization of BT boost declined from 2.1% in 2004 to 0.2% in 2012 (p < 0.0001), whereas intensity-modulated radiation therapy use increased from 22.8% in 2004 to 69.2% in 2012 (p < 0.0001). The three- and 5-year OS was 83.2% and 78.3% for patients receiving EBRT + BT compared with 77.4% and 69.0% for those receiving EBRT only (p = 0.03). The difference in survival was significantly better among patients with T3-4 tumors with EBRT + BT boost (p = 0.009) however, there was no survival benefit among patients with T1-2 tumors (p = 0.72). The analysis was repeated with patients who received intensity-modulated radiation therapy vs. EBRT with BT boost and the survival difference was sustained only for those with T3-4 tumors (p = 0.02). CONCLUSIONS: Brachytherapy boost has decreased in its utilization even though it was associated with favorable survival outcomes particularly among patients with higher T-stage tumors.
PMID: 28943128
ISSN: 1873-1449
CID: 2717812
Intensity modulated radiation therapy improves survival in early-stage supraglottic larynx cancer [Meeting Abstract]
Wu, S P P; Cohen, P; Tam, M; Schreiber, D; Gerber, N K; Givi, B; Hu, K S
Purpose/Objective(s): Early stage supraglottic larynx cancers treated with definitive radiotherapy (RT) require treatment of the bilateral neck because of high rates of regional spread. Compared to older techniques, modern intensity modulated radiation therapy (IMRT) has been shown to precisely target tumor and draining nodal regions with the potential to spare organs at risk including those essential for prevention of aspiration. However, previous hospital-based studies have demonstrated decreased survival associated with the use of IMRT compared to 3D and 2D radiotherapy techniques in glottic larynx. We used the National Cancer Data Base (NC
EMBASE:618559676
ISSN: 0360-3016
CID: 2752282
Patterns of Care and Outcomes of Adjuvant Therapy for High Risk Head and Neck Cancer After Surgery [Meeting Abstract]
Osborn, VW; Givi, B; Roden, DF; Katsoulakis, E; Sheth, N; Lederman, AJ; Schwartz, D; Schreiber, D
ISI:000411559103033
ISSN: 1879-355x
CID: 2766862
The Novel Anti-CD40 Monoclonal Antibody CFZ533 Shows Beneficial Effects in Patients with Primary Sjogren's Syndrome: A Phase IIa Double-Blind, PlaceboControlled Randomized Trial [Meeting Abstract]
Wu, SPP; Cohen, P; Tam, M; Schreiber, D; Gerber, NK; Givi, B; Hu, KS
ISI:000411559103080
ISSN: 2326-5205
CID: 2767272
Intensity Modulated Radiation Therapy With Concurrent Chemotherapy for Larynx Preservation in Locally Advanced Larynx Cancer: A National Cancer Database Study [Meeting Abstract]
Wu, SPP; Tam, M; Shaikh, F; Schreiber, D; Gerber, NK; Givi, B; Hu, KS
ISI:000411559103079
ISSN: 1879-355x
CID: 2767282
Radiation Therapy Dose and Survival Outcomes in Human Papillomavirus (HPV)-Positive Oropharyngeal Cancer [Meeting Abstract]
Tam, M; Wu, P; Gerber, NK; Schreiber, D; Givi, B; Hu, KS
ISI:000411559103062
ISSN: 1879-355x
CID: 2767292